Q2 EPS Estimates for Beam Therapeutics Reduced by Wedbush
Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) – Equities researchers at Wedbush cut their Q2 2025 earnings estimates for Beam Therapeutics in a report released on Tuesday, May 6th. Wedbush analyst D. Nierengarten now expects that the company will earn ($1.05) per share for the quarter, down from their previous forecast of ($0.97). Wedbush has […]
Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) – Equities researchers at Wedbush cut their Q2 2025 earnings estimates for Beam Therapeutics in a report released on Tuesday, May 6th. Wedbush analyst D. Nierengarten now expects that the company will earn ($1.05) per share for the quarter, down from their previous forecast of ($0.97). Wedbush has […]
